secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019433
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Q1 net sales down 38% to $3.6M; loss narrows; Aditxt merger progress
---------------------------------------------------------------------------

- Net sales $3.6M vs $5.8M a year ago, attributed to WAC increase cycle and Change Healthcare cyberattack.
- Loss from operations narrowed 21% to $2.8M; total operating expenses decreased 31% to $6.4M.
- Received $1M from Aditxt in May; Aditxt to invest additional $2.5M by July 1, 2024; merger expected H2 2024.
- USPTO allowed new Phexxi composition-of-matter patent; fifth U.S. patent covering the drug.
- Medi-Cal rebate reduced 7.4% effective July 1, 2024, improving net pricing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224019433/0001493152-24-019433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224019433/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer